Navigation Links
Molecule May Trigger Psoriasis
Date:1/18/2008

Study in mice offers hope for new treatment of chronic skin disease

FRIDAY, Jan. 18 (HealthDay News) -- A molecule may play a major role in the development of psoriasis, offering a new way to treat this chronic skin disease, a study finds.

A team at Wyeth Research, in Cambridge, Mass., found that antibodies that neutralized the IL-22 molecule in mice prevented the development of psoriasis-like lesions. The researchers also found injecting IL-22 into the skin of normal mice activated genes associated with the development of psoriasis-like skin lesions.

These findings, published in the Jan. 17 issue of the Journal of Clinical Investigation, suggest that targeting IL-22 may provide a new approach to treating people with psoriasis, the study authors said.

Psoriasis, which causes red, scaly, raised skin lesions, affects up to 3 percent of the world's population and more than 7.5 million Americans, according to the National Psoriasis Association.

More information

The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more about psoriasis.



-- Robert Preidt



SOURCE: Journal of Clinical Investigation, news release, Jan. 17, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Alzheimers molecule is a smart speed bump on the nerve-cell transport highway
2. Molecules might identify high-risk acute-leukemia patients
3. Common molecule notifies immune system of prostate cancer
4. Tiny RNA Molecules Control Breast Cancers Spread
5. Molecules can block breast cancers ability to spread
6. Major Advance in the Observation of DNA Molecules
7. St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases
8. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
9. Researchers identify molecules with interesting anti-clotting properties
10. Study Describes Molecules That Control Blood Pressure
11. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Molecule May Trigger Psoriasis
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Finally, a bruise ... venous procedures, dermaka cream can be incorporated into the post-surgical treatment plans of a ... procedures. , dermaka cream is very effective for bruising and causes a rapid ...
(Date:6/24/2016)... ... 24, 2016 , ... Southern Illinois University School of Dental ... Illinois State Dental Society (ISDS) Foundation’s Mission of Mercy (MOM). They will host ... Collinsville. , They expect to treat approximately 2,000 patients from Illinois, ...
(Date:6/24/2016)... ... June 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona ... surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new ... Lodge at Sedona as well as the Sedona Rouge, both popular accommodations for SpiritQuest ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology: